Randomized prospective phase ii study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 3, 2012, Pages 237-241

  Ocvirk, Janja ^a   Reberšek, Martina ^a   Škof, Erik ^a   Hlebanja, Zvezdana ^a   Boc, Marko ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

5 fluorouracil; capecitabine; cisplatin; epirubicin; gastric cancer

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTATIC GASTRIC CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; ONCOLOGICAL PARAMETERS; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHLEBITIS; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; STOMATITIS; THERAPY EFFECT; THROMBOCYTOPENIA; TIME TO PROGRESSION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PERITONEAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84861528754     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31820dc0b0     Document Type: Article

References (23)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 CA Cancer J Clin. 2005;55:74-108
2. Cancer Registry of Republic of Slovenia. Cancer incidence in Slovenia 2007. Report no. 78. Available at: http://www.onko-i.si/ fileadmin/onko/ datoteke/dokumenti/LP-2007.pdf. Accessed June 22, 2010.
3. Ajani JA. Evolving chemotherapy for adVanced gastric cancer Oncologist. 2005;10(suppl 3):49-58
4. Felici A, Carlini P, Ruggeri EM, et al. Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in adVanced gastric cancer: a multicentric phase II study. Cancer Chemother Pharmacol. 2006;57:59-64
5. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in adVanced gastric cancer: a systemic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903-2909
6. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in adVanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004
7. Bamias A, Hill ME, Cunningham D, et al. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival. Cancer. 1996;77:1978-1985
8. Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Brit J Cancer. 1999; 80:269-272
9. Zaniboni A, Barni S, Labianca R, et al. Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with adVanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report. Cancer. 1995; 76:1694-1699
10. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in adVanced esophagogastric cancer. J Clin Oncol. 1997;15:261-267
11. Findlay M, Cunningham D, Norman A, et al. A phase II study in adVanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 1994;5:609-616
12. Das P, Ajani JA. Gastric and gastro-oesophageal cancer therapy xpert Opin Pharmacother. 2005;6:2805-2812
13. Ohtsu A. Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer. 2005;8:95-102
14. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration an adVanced colorectal cancer. J Clin Oncol. 1998;16:301-308
15. EVans TR, Pentheroudakis G, Paul J, et al. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophagogastric adenocarcinoma. Ann Oncol. 2002;13:1469-1478
16. Koizumi W, Saigenji K, Ujiie S, et al. A pilot phase II study of capecitabine in adVanced or recurrent gastric cancer. Oncology 2003;64:232-236
17. Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with adVanced and/or metastatic gastric cancer. Ann Oncol. 2004;15:1344-1347
18. Kim TW, Kang YK, Ahn JH, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in adVanced gastric cancer. Ann Oncol. 2002;13:1893-1898
19. Cho EK, Lee WK, Im SA, et al. A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or adVanced gastric cancer. Oncology 2005;68:333-340
20. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for adVanced esophagogastric cancer. N Engl J Med 2008;358:36-46
21. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin as first-line therapy in patients with adVanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666-673
22. Okines AF, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of adVanced oesophago-gastric cancer. Ann Oncol. 2009;20:1529-1534
23. O'Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009;15(15):4806-4814